Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07534592) titled 'A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants' on April 10.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: AstraZeneca
Condition:
Healthy Participants
Intervention:
Drug: Elecoglipron
Drug: Atorvastatin
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: April 12, 2026
Target Sample Size: 40
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/stud...